NCT02739412View on ClinicalTrials.gov

Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Liver Transplantation
Interventions
BIOLOGICAL

Interleukin-2

Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Beth Israel Deaconess Medical Center

OTHER

NCT02739412 - Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients | Biotech Hunter | Biotech Hunter